Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Warner Bros. Discovery Weighs Renewed Sale Talks With Paramount Skydance Amid Netflix Deal Review 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
WALTHAM, Mass., April 24, 2018 -- Radius Health (Nasdaq:RDUS) announced today that it will release its first quarter financial results on Thursday, May 10, 2018. The Company will host a conference call and live audio webcast at 8:00 a.m. ET that day to discuss the results and provide a company update.
Conference Call Information:
Date: Thursday, May 10, 2018
Time: 8:00 a.m. ET
Domestic Dial-in Number: (866) 323-7965
International Dial-in Number: (346) 406-0961
Conference ID: 6964878
Live webcast: https://edge.media-server.com/m6/p/y98kugt8
A replay of the conference call/webcast will be available from May 10, 2018 at 7:30 p.m. ET until May 17, 2018 at 6:30 p.m. ET. To access the replay, dial (855) 859-2056 for U.S. or (404) 537-3406 for International. The replay conference ID is 6964878.
The live audio webcast of the call can be accessed from the Investors section of the Company's website, www.radiuspharm.com. A webcast replay will also be available for 14 days. The full text of the announcement and financial results will also be available on the Company's website.
About Radius
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant RAD1901 for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit www.radiuspharm.com.
Investor Relations Contact:
Elhan Webb, CFA
Email: [email protected]
Phone: 617-551-4011
